01—Abstract
Summary
Summary of the 8-K filed April 3, 2025. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) filed an 8-K report on April 2, 2025, providing a preliminary update on its first quarter 2025 financial performance.
The company expects to incur approximately $248 milliona in acquired In-Process Research & Development (IPR&D) and milestones expense on a pre-tax basis during the first quarter. This expense is estimated to have an unfavorable impact of $0.13 on both GAAP and adjusted non-GAAP diluted earnings per share (EPS). While this expense was not previously forecasted in the company's initial 2025 guidance, AbbVie has updated its full-year 2025 adjusted diluted EPS guidance to a range of $11.99 - $12.19.
The updated first quarter 2025 adjusted diluted EPS guidance is now $2.34b - $2.38. Investors should note that this guidance does not include the impact of the licensing agreement with Gubra for GUB014295, as that transaction closed after the first quarter. The company emphasizes that these are preliminary estimates and actual results are subject to finalization.
02—Key points
Key Highlights
- AbbVie anticipates $248 million in pre-tax acquired IPR&D and milestones expense for Q1 2025.
- This expense is projected to negatively impact Q1 GAAP and adjusted non-GAAP EPS by $0.13.
- Full-year 2025 adjusted diluted EPS guidance is revised to $11.99 - $12.19.
- Q1 2025 adjusted diluted EPS guidance is updated to $2.34 - $2.38.
- Guidance excludes the impact of the recent Gubra licensing agreement for GUB014295, which closed post-Q1.
- The reported figures are preliminary estimates and subject to change upon final financial statement closing.
- AbbVie does not typically forecast acquired IPR&D and milestones expenses due to inherent uncertainty.
03—Questions
Frequently Asked Questions
What is the primary reason for AbbVie's preliminary Q1 2025 results update?
AbbVie is providing an update due to an anticipated $248 million in pre-tax acquired IPR&D and milestones expense in the first quarter of 2025, which was not previously included in financial forecasts.
How does this acquired IPR&D expense affect AbbVie's earnings per share?
The acquired IPR&D and milestones expense is expected to reduce both GAAP and adjusted non-GAAP diluted earnings per share (EPS) by $0.13 for the first quarter of 2025.
What are the updated full-year and Q1 2025 adjusted EPS guidance ranges?
The updated full-year 2025 adjusted diluted EPS guidance is now $11.99 - $12.19. The updated Q1 2025 adjusted diluted EPS guidance is $2.34 - $2.38, which includes the impact of the acquired IPR&D and milestones expense.
Does the updated guidance include the Gubra licensing agreement?
No, the updated guidance does not reflect the impact of the licensing agreement with Gubra for GUB014295, as that transaction was completed after the first quarter of 2025.
04—Continue